Effect of combined chromium and carnitine supplementation in treatment of women with polycystic ovary syndrome

Phase 3

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20170513033941N38
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Patients with polycystic ovary syndrome
Individuals aged 18 to 40 years.

Exclusion Criteria

Pregnancy
Adrenal hyperplasia
Androgen-secreting tumors
Thyroid dysfunction
Diabetes
Hyperprolactinemia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.

Secondary Outcome Measures

Name	Time	Method
Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT-1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LDL-R gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.